HABIBATU SESAY: Open Payments
NPI 1043852023 · NORTH POTOMAC, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,727 in 74 payments from 13 companies in 2025. Trend: 2023 $1,261 · 2024 $1,351 · 2025 $1,727
Food & beverage: $1,723Education: $4
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $338 |
| Teva Pharmaceuticals USA, Inc. | 7 | $285 |
| Otsuka America Pharmaceutical, Inc. | 15 | $235 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $209 |
| Neurocrine BioSciences, Inc. | 8 | $172 |
| Lundbeck LLC | 8 | $164 |
| Supernus Pharmaceuticals, Inc. | 3 | $133 |
| Alkermes, Inc. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $36 |
Products named: VRAYLAR, REXULTI, UZEDY, CAPLYTA, INGREZZA, Qelbree, ABILIFY MAINTENA, ARISTADA.
Industry payments across MD — which companies pay providers there.
